Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Orthopaedics
  • Orthopaedics News
  • Dotinurad Outperforms...

Dotinurad Outperforms Febuxostat in Reducing Uric Acid Levels in Gout Patients, EULAR 2024 Reports

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-07-14T20:45:03+05:30  |  Updated On 14 July 2024 8:45 PM IST
Dotinurad Outperforms Febuxostat in Reducing Uric Acid Levels in Gout Patients, EULAR 2024 Reports
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

China: In a study involving Chinese patients with gout, dotinurad 4 mg was found to be more effective than febuxostat 40 mg in reducing serum uric acid (sUA) levels, as reported at the 2024 European Congress of Rheumatology (EULAR). Furthermore, dotinurad 2 mg demonstrated non-inferiority to febuxostat and was well-tolerated by patients.

Gout is a painful arthritis caused by high uric acid levels, leading to joint inflammation. Dotinurad is a novel, selective urate reabsorption inhibitor approved in 2020 for treating hyperuricemia and gout in Japan. The drug lowers serum uric acid levels by selectively inhibiting the urate transporter. Febuxostat, a non-purine xanthine oxidase inhibitor, is a widely used treatment for urate reduction.

Previous research has evaluated the efficacy and safety of dotinurad in patients with hyperuricemia with or without gout. The systematic review and meta-analysis used an electronic database search to identify eligible randomized controlled trials. Results revealed significant improvements in sUA levels among patients with hyperuricemia treated with dotinurad, comparable to other commonly available anti-hyperuricemic drugs, and was effective at doses 1 mg, 2 mg, and 4 mg.

The current multicenter, double-blind, active-controlled, parallel-group, phase 3 study evaluated the safety and efficacy of dotinurad compared to febuxostat in patients with gout. Eligible participants had serum uric acid (sUA) levels greater than 7.0 mg/dL. Subjects were randomly assigned in a 1:1 ratio to receive either dotinurad, starting at 1 mg/day for four weeks, then 2 mg/day for eight weeks, and finally 4 mg/day for 12 weeks, or febuxostat, which was administered at 20 mg/day for four weeks followed by 40 mg/day for 20 weeks. Randomization was stratified based on baseline sUA levels (<9, 9–<10, 10–<11, and ≥11 mg/dL) and body mass index (BMI) categories (<25 and ≥25 kg/m²).

The primary outcome was the percentage of participants achieving serum uric acid (sUA) levels of ≤ 6.0 mg/dL by week 24, while the secondary outcome focused on those reaching this level by week 12. The non-inferiority margin was set at -10%. For participants with missing sUA values, the most recent post-baseline data were utilized for efficacy analysis.

A total of 451 patients were included in the study, of which 225 were in the dotinurad cohort, and 226 in the febuxostat cohort. The full analysis set (FAS) included 220 receiving dotinurad and 221 receiving febuxostat. Baseline characteristics were comparable across treatment groups. The majority (98.2%) were male, the median age was 38 years, and 72.8 (n = 321) had a baseline body mass index of ≥ 25 kg/m2. The mean sUA at baseline was 9.66 mg/dL, and the mean time since gout diagnosis was 5.34 years. Most (95.9%) had previously reported gouty arthritis.

The study led to the following findings:

  • A significantly larger proportion of patients in the dotinurad group (73.6%) met the primary endpoint compared with 38.1% in the febuxostat group at week 24.
  • The 4 mg dose of dotinurad demonstrated superiority to febuxostat 40 mg, with a treatment difference of 35.87%.
  • 2 mg proved non-inferiority to febuxostat, with a difference of 5.24% (55.5% versus 50.5%, respectively).
  • The most reported treatment-emergent adverse events were gouty arthritis (43.5%), COVID-19 (25.6%), and abnormal hepatic function (10.8%) in the dotinurad cohort and gouty arthritis (34.7%), COVID-19 (25.3%), and increased alanine aminotransferase (12.4%) among those in the febuxostat cohort.
  • The safety profile was comparable across treatment arms; there were no new safety concerns in either cohort.

"The findings showed that dotinurad 4 mg is superior to febuxostat 40 mg for gout treatment," the researchers concluded. "Also, dotinurad 2 mg was non-inferior to febuxostat, and the drug was well-tolerated."

Reference:

Sun J, Wang Y, Zhang X, Guo D, et al. A Randomized Multicenter, Double-Blind, Phase 3 Study Comparing Efficacy of Dotinurad and Febuxostat for the Treatment of Gout in Chinese Subjects.Presented at: EULAR. Vienna, Austria. June 12 – 15, 2024.


European Congress of Rheumatologydotinuradgoutserum uric acidfebuxostat
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Prediabetes and the Mind: Unraveling Cognitive and Mental Health Risks

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    View All

    Journal Club Today

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    Is Fitness Overrated? Study Questions the True Impact of Fitness on Early Death

    View All

    Health News Today

    Health Bulletin 17/ May/ 2025

    Health Bulletin 17/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok